Abstract
The eye is an immune-privileged site and is more amenable to genetic therapy. A number of diseases in the posterior segment of the eye have genetic origin. The posterior segment of the eye is difficult to access. But routes to deliver drugs and genes have been worked upon. The genetic therapy ensures long-term treatment of the disease in the eye. The genes that are to be delivered to their proper site can be given through viral and non-viral vectors. Viral vectors offer a number of advantages when it comes to transfection efficiency and gene expression but are associated with immunity issues and cannot be loaded with genes which are more than 5 kb. Over the years non-viral gene vectors are becoming increasingly popular because of their higher gene loading capacity and number of distinct advantages over the viral vectors. But the genes that are to be delivered to the nucleus have to escape a number of degradative mechanisms outside and inside the cell to reach the nucleus. Lipoplexes and polyplexes have been successfully used in the treatment in nonclinical studies, but the clinical applications have still to see the light of the day.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Adijanto J, Naash MI. Nanoparticle-based technologies for retinal gene therapy. Eur J Pharm Biopharm. 2015;95:353–67.
Conley SM, Cai X, Naash MI. Non-viral ocular gene therapy: assessment and future directions. Curr Opin Mol Ther. 2008;10(5):456–63.
Edelhauser HF, et al. Ophthalmic drug delivery systems for the treatment of retinal diseases: basic research to clinical applications. Invest Ophthalmol Vis Sci. 2010;51(11):5403–20.
Kaur IP, Kakkar S. Nanotherapy for posterior eye diseases. J Control Release. 2014;193:100–12.
Nayerossadat N, Maedeh T, Ali PA. Viral and nonviral delivery systems for gene delivery. Adv Biomed Res. 2012;1:27.
Petit L, Khanna H, Punzo C. Advances in gene therapy for diseases of the eye. Hum Gene Ther. 2016;27(8):563–79.
Pollard H, Remy JS, Loussouarn G, Demolombe S, Behr JP, Escande D. Polyethylenimine but not cationic lipids promotes transgene delivery to the nucleus in mammalian cells. J Biol Chem. 1998;273:7507–11.
Ramamoorth M, Narvekar A. Non viral vectors in gene therapy- an overview. J Clin Diagn Res. 2015;9(1):GE01–6.
Thakur A, et al. Strategies for ocular siRNA delivery: potential and limitations of non-viral nanocarriers. J Biol Eng. 2012;6:7.
Tros de Ilarduya C, Sun Y, Duzgunes N. Gene delivery by lipoplexes and polyplexes. Eur J Pharm Sci. 2010;40(3):159–70.
Zulliger R, Conley SM, Naash MI. Non-viral therapeutic approaches to ocular diseases: an overview and future directions. J Control Release. 2015;219:471–87.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer International Publishing AG, part of Springer Nature
About this chapter
Cite this chapter
Lalwani, A., Shelat, P., Patel, J.K. (2018). Nanomedicine-Based Gene Delivery for the Retina and Posterior Segment Diseases. In: Patel, J., Sutariya, V., Kanwar, J., Pathak, Y. (eds) Drug Delivery for the Retina and Posterior Segment Disease. Springer, Cham. https://doi.org/10.1007/978-3-319-95807-1_16
Download citation
DOI: https://doi.org/10.1007/978-3-319-95807-1_16
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-95806-4
Online ISBN: 978-3-319-95807-1
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)